Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | BACE1 | P56817 | 7/20 | 0.44 |
| ▸ | CTSD | P07339 | 5/20 | 0.44 |
| ▸ | SMYD3 | Q9H7B4 | 2/20 | 0.41 |
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | CARM1 | Q86X55 | 3/20 | 0.39 |
| ▸ | PRMT6 | Q96LA8 | 3/20 | 0.39 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5022826 | 0.93 | ALDH1A1 (0.51) | ALDH1A1BACE1CTSDACHEPOLB | |
| SCHEMBL19008147 | 0.87 | ALDH1A1 (0.47) | ALDH1A1BACE1CTSDACHEPOLB | |
| SCHEMBL19008153 | 0.87 | ALDH1A1 (0.56) | ALDH1A1BACE1CTSDACHEPOLB | |
| SCHEMBL18626538 | 0.87 | ALDH1A1 (0.60) | ALDH1A1BACE1CTSDACHEPOLB | |
| SCHEMBL19008149 | 0.83 | ALDH1A1 (0.46) | ALDH1A1BACE1CTSDACHEPOLB | |
| SCHEMBL15587414 | 0.81 | ACHE (0.60) | ALDH1A1BACE1SMYD3ACHEPOLB | |
| SCHEMBL19008152 | 0.79 | BACE1 (0.52) | ALDH1A1BACE1CTSD | |
| SCHEMBL19008166 | 0.78 | BACE1 (0.47) | ALDH1A1BACE1CTSDCARM1PRMT6 | |
| SCHEMBL29577342 | 0.78 | CARM1 (0.56) | ALDH1A1BACE1ACHEPOLBCARM1 | |
| SCHEMBL18626511 | 0.77 | MAP4K4 (0.37) | BACE1CTSDSMYD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9855269-B2 | Aminoquinazoline and pyridopyrimidine derivatives | GENENTECH, INC. (US) | 2018-01-02 | — | — | US | disclosed |
| US-20170173026-A1 | AMINOQUINAZOLINE AND PYRIDOPYRIMIDINE DERIVATIVES | GENENTECH, INC. (US) | 2017-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170173026-A1 | AMINOQUINAZOLINE AND PYRIDOPYRIMIDINE DERIVATIVES | FLT4, FLT1, KDR | ALDH1A1 586/4885BACE1 3929/4885CTSD 3865/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.